Medical Economics, May 9, 2024: House Small Business Committee hearing focused on when government regulations undermine medical innovation and services but also agreed on the need to ensure safe and effective medical products.
Read More »Author: Caroline Bradford
Diana Zuckerman Comments on the U.S. Consumer Product Safety Commission Priorities for FY2025/2026
May 8, 2024: NCHR recommended that Consumer Product Safety Commission FY 2025-26 priorities include reducing exposures to PFAS and other chemicals, lead, and heavy metals in tire crumb used in homes, backyards, daycare, playgrounds, and artificial turf fields.
Read More »Testimony of Dr. Diana Zuckerman at the House Small Business Committee Hearing
May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in health care.
Read More »NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
April 29, 2024: NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Read More »NCHR Comment on Petition Requesting Rulemaking To Mandate Testing and Labeling Regarding Slip Resistance of Flooring, Floor Coatings and Treatments, Floor Cleaning Agents, and Footwear
April 22, 2024: NCHR supports CPSC’s slip resistance testing proposal for flooring but urges more comprehensive safety standards that also evaluate exposure to dangerous chemicals and heavy metals, such as those in rubber flooring.
Read More »